Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference
01/06/2022 - 08:00 AM
Webcast Available On Demand Beginning at 7:00 a.m. ET Monday, January 10
LEXINGTON, Mass. --(BUSINESS WIRE)--
Aldeyra Therapeutics, Inc. Todd C. Brady , M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference .
Dr. Brady’s conversation with Edwin Zhang , Ph.D., MBA, Managing Director and Senior Healthcare Analyst for H.C. Wainwright, will be available on demand beginning at 7:00 a.m. ET Monday, January 10, 2022 . To view the webcast, log in to the Investors & Media section of the Aldeyra Therapeutics website at https://ir.aldeyra.com . The event will remain archived on the website for 90 days.
About Aldeyra Therapeutics
Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies designed to modulate immunological systems, without inhibiting or activating single targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, atopic asthma, and COVID-19. Our clinical pipeline also includes ADX-2191 (intravitreal methotrexate 0.8% ), in Phase 3 clinical testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn , Facebook , and Twitter .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220105005960/en/
Corporate:
Joshua Reed
Aldeyra Therapeutics, Inc.
jreed@aldeyra.com
Investors & Media:
Scott Solomon
Sharon Merrill Associates, Inc.
ALDX@investorrelations.com
Source: Aldeyra Therapeutics, Inc.
ALDX Rankings
#5198 Ranked by Stock Gains
ALDX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About ALDX
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
